Business
Research Programme Update
Research Programme Update.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n Sareum Holdings PLC\n06 February 2007\n\n\nFor immediate release 6 February 2007\n\n\n\n SAREUM HOLDINGS PLC, THE INSTITUTE OF CANCER RESEARCH AND CANCER RESEARCH\n TECHNOLOGY LTD\n\n\n\n\n\n Progression of Checkpoint Kinase 1 Drug Discovery Programme\n\n\n\nSareum Holdings plc (Sareum) (AIM: SAR), the specialist structure-based drug\ndiscovery business, The Institute of Cancer Research (The Institute), Europe's \nleading cancer research centre, and Cancer Research Technology Limited (CRT), \nthe oncology focused development and commercialisation company, are pleased \nto announce that novel small molecule compounds, the subject of a series of \npatent filings, show activity in targeting Checkpoint Kinase 1 (CHK1).\n\nCHK1 is a key component of a biochemical pathway responsible for preventing the\neffectiveness of traditional cancer therapeutics such as chemotherapy and is the\nprimary target of the joint collaboration. The aim of the programme, first\nannounced in July 2005, is to develop potential cancer treatments with valuable\nbenefits for cancer patients including lower doses of existing therapies, fewer\nadverse side-effects and efficacy where tumours currently do not respond to\nchemotherapy. In August 2006 Sareum announced that the collaboration had\ndiscovered a novel compound series which showed activity in cancer cell models.\n\nThe patent filings are part of an ongoing strategy to secure the intellectual\nproperty rights relating to the novel compound series developed from this\ncollaboration, their effectiveness in inhibiting CHK1 function and their use in\nthe treatment of cancer.\n\nSareum has used its expertise in fragment and structure-based drug discovery to\nidentify novel chemical compounds effective against CHK1. These compound series\nhave been rapidly progressed towards drug candidates utilising Sareum[?c=8217]s\nhigh throughput medicinal chemistry and structure determination platforms\ncombined with the drug screening, specialist cancer biology and medicinal\nchemistry expertise at The Cancer Research UK Centre for Cancer Therapeutics at\nThe Institute.\n\nUnder the terms of the collaboration agreement, CRT will commercialise the drug\ncandidates developed by the collaboration to secure future clinical development.\nPayments, milestones and royalties received by CRT will be shared with Sareum\nand The...